{"id":"asc40-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated transaminases"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3661754","moleculeType":"Small molecule","molecularWeight":"439.56"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ASC40 targets the HBV core antigen and inhibits capsid assembly, preventing the formation of infectious viral particles. This mechanism differs from nucleos(t)ide reverse transcriptase inhibitors and represents a novel approach to HBV treatment by directly interfering with virion maturation rather than viral replication.","oneSentence":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:08.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT06248008","phase":"PHASE3","title":"A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2024-04-18","conditions":"Acne","enrollment":240},{"nctId":"NCT06192264","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2024-01-23","conditions":"Acne","enrollment":480},{"nctId":"NCT05104125","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-12","conditions":"Acne Vulgaris","enrollment":180},{"nctId":"NCT05118776","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2022-01-21","conditions":"Recurrent Glioblastoma","enrollment":136},{"nctId":"NCT04843449","phase":"PHASE1","title":"Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects","status":"COMPLETED","sponsor":"Ascletis Pharmaceuticals Co., Ltd.","startDate":"2021-04-04","conditions":"Healthy","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TVB-2640"],"phase":"phase_3","status":"active","brandName":"ASC40 tablets","genericName":"ASC40 tablets","companyName":"Ascletis Pharmaceuticals Co., Ltd.","companyId":"ascletis-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation. Used for Chronic hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}